Cerulean Pharma Inc. (DARE) Receives Average Recommendation of “Hold” from Brokerages
Shares of Cerulean Pharma Inc. (NASDAQ:DARE) have been given a consensus rating of “Hold” by the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $3.00.
Separately, ValuEngine raised shares of Cerulean Pharma from a “sell” rating to a “hold” rating in a research note on Saturday.
Shares of Cerulean Pharma (DARE) traded up 2.28% during trading on Monday, reaching $5.38. 84,189 shares of the company’s stock were exchanged. The firm’s market cap is $15.62 million. Cerulean Pharma has a 52 week low of $3.23 and a 52 week high of $35.80.
TRADEMARK VIOLATION WARNING: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/24/cerulean-pharma-inc-dare-receives-average-recommendation-of-hold-from-brokerages.html.
About Cerulean Pharma
Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.
Receive News & Ratings for Cerulean Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.